Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | TOP2A | P11388 | 8/20 | 0.37 |
| ▸ | TOP2B | Q02880 | 8/20 | 0.37 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13945282 | 1.00 | ADRB2 (0.40) | ADRB2TOP2ATOP2BSTAT3CNR1 | |
| SCHEMBL3815792 | 0.88 | CYP3A4 (0.41) | ADRB2TOP2ATOP2BSTAT3CNR1 | |
| SCHEMBL762152 | 0.88 | CYP3A4 (0.41) | ADRB2TOP2ATOP2BSTAT3CNR1 | |
| SCHEMBL6953927 | 0.88 | CYP3A4 (0.41) | ADRB2TOP2ATOP2BSTAT3CNR1 | |
| SCHEMBL10306128 | 0.88 | CYP3A4 (0.41) | ADRB2TOP2ATOP2BSTAT3CNR1 | |
| SCHEMBL12427281 | 0.88 | CYP3A4 (0.41) | ADRB2TOP2ATOP2BSTAT3CNR1 | |
| SCHEMBL2184241 | 0.87 | ADRB2 (0.51) | ADRB2TOP2ATOP2BKCNH2ALDH1A1 | |
| SCHEMBL14387678 | 0.87 | KCNH2 (0.41) | ADRB2TOP2ATOP2BSTAT3CNR1 | |
| SCHEMBL14387590 | 0.87 | KCNH2 (0.41) | ADRB2TOP2ATOP2BSTAT3CNR1 | |
| SCHEMBL13483643 | 0.86 | STAT3 (0.51) | ADRB2TOP2ATOP2BSTAT3CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476429-B2 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-02 | — | — | US | disclosed |
| US-8476429-B2 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-02 | — | — | US | disclosed |
| US-8455482-B2 | Substituted pyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-06-04 | — | — | US | disclosed |
| US-8455482-B2 | Substituted pyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-06-04 | — | — | US | disclosed |
| US-8455482-B2 | Substituted pyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-06-04 | — | — | US | disclosed |
| US-20120232288-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2012-09-13 | — | — | US | disclosed |
| US-8211910-B2 | Tri-, tetra-substituted-3-aminopyrrolidine derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2012-07-03 | — | — | US | disclosed |
| US-7977327-B2 | Substituted pyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977327-B2 | Substituted pyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20110166131-A1 | SUBSTITUTED PYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-07-07 | — | — | US | disclosed |
| US-20110166131-A1 | SUBSTITUTED PYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2011-07-07 | — | — | US | disclosed |
| US-20090253726-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-10-08 | — | — | US | disclosed |
| US-7563805-B2 | 7-[3-Amino-3,4-dimethylpyrrolidine-1-yl]-6-fluoro-1-[(1R,2S)-2-fluorocyclopropyl]-1,4-dihydro-8-methyl-4-oxoquinoline-3-carboxylic acid: quinoline bactericide; broad spectrum, strong antibacterial activity for Grampositive/-negative including multiple resistant cocci; side effect reductcion; drug design | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-07-21 | — | — | US | disclosed |
| US-20090012119-A1 | FLUOROALKYLPYRROLIDINE DERIVATIVE | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-01-08 | — | — | US | disclosed |
| US-20080045520-A1 | Substituted Pyrrolidine Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-02-21 | — | — | US | disclosed |
| US-20080045520-A1 | Substituted Pyrrolidine Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-02-21 | — | — | US | disclosed |
| EP-1757598-A1 | SUBSTITUTED PYRROLIDINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012119-A1 | FLUOROALKYLPYRROLIDINE DERIVATIVE | FPR1, VIP, Q6ZSR9 | ADRB2 1863/4885TOP2A 715/4885TOP2B 917/4885 |
| US-20090253726-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | AAAS, NPEPPS, TEAD4 | ADRB2 3111/4885TOP2A 23/4885TOP2B 69/4885 |
| US-20110166131-A1 | SUBSTITUTED PYRROLIDINE DERIVATIVE | AQP1, GLUL, GATD3 | ADRB2 3505/4885TOP2A 23/4885TOP2B 62/4885 |
| US-20120232288-A1 | TRI-, TETRA-SUBSTITUTED-3-AMINOPYRROLIDINE DERIVATIVE | TLR5, TEAD4, NAALAD2 | ADRB2 3348/4885TOP2A 43/4885TOP2B 165/4885 |
| US-20080045520-A1 | Substituted Pyrrolidine Derivative | QPCT, GMPS, QPCTL | ADRB2 3852/4885TOP2A 68/4885TOP2B 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.